Latest news

• Teva suffers setback as Nuvigil fails late-stage trial

  Nuvigil (armodafinil) did not show a significant improvement over placebo when added on to therapy with mood stabilisers or atypical antipsychotics in the study, which involved patients with major depression associated

• Teva sees Q2 profits leap as US business recovers

  Other strong performers were Parkinson's disease drug Azilect (rasagiline), up 36 per cent to $95m, while Cephalon products Treanda (bendamustine) for leukaemia and narcolepsy treatment Nuvigil  (armodafinil) added $139m and

• Cephalon jet lag application rejected

  Cephalon has dropped its bid to get its sleep disorder drug Nuvigil (armodafinil) approved as a treatment for jet lag after the marketing application was rejected by the US Food and

• State of mind

  Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders. ... A phase II trial is currently underway to assess the efficacy of armodafinil in patients with bipolar depression.